The Effect of MSCs Derived from the Human Umbilical Cord Transduced by Fibroblast Growth Factor-20 on Parkinson's Disease.
Cell therapy is a potential therapeutic approach for Parkinson's disease (PD). Mesenchymal stem cells derived from the human umbilical cord (hUC-MSCs) give priority to PD patients because of multiple advantages. The appropriate gene transduction of hUC-MSC before transplantation is a promising procedure for cell therapy. Fibroblast growth factor-20 (FGF-20) has been shown to protect dopaminergic neurons against a range of toxic insults in vitro. In this study, the hUC-MSCs were gene transduced with FGF-20, and then we transplanted them into the PD mice model. The results showed that MSC-FGF-20 treatment obviously improved the behavior of PD, accompanied by the increase of tyrosine carboxylase- (TH-) positive cell and dopamine (DA). Furtherly, immunohistochemistry disclosed that MSC-FGF-20 obviously promoted the degradation of nuclear factor-κB (NF-κB), a transcription factor that controls genes encoding proinflammatory cytokines, highly expressed in the nigrostriatal dopaminergic regions in PD patients. Therefore, MSC-FGF-20 has a potential for improving PD, closely related to the degradation of NF-κB.
Neurology Department, General Hospital of Jinan Military Region, Jinan, Shandong 250031, China.
Li
L
Jinfeng
Neurology Department, The Second Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450014, China; Neurology Department, The 148th Hospital, Zibo, Shandong 255300, China.
Wang
W
Yunliang
Sanbo Brain Hospital, Capital Medical University, Haidian District, Beijing 100093, China.
Liu
L
Xinshan
Neurology Department, The 148th Hospital, Zibo, Shandong 255300, China.
Wang
W
Shanshan
Neurology Department, The Second Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450014, China.
Xu
X
Chunyang
Neurology Department, The Second Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450014, China.
Xue
X
Peng
Neurology Department, The Second Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450014, China.
Yang
Y
Xiaopeng
Neurology Department, The Second Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450014, China.
Xu
X
Zhixiu
Neurology Department, The 148th Hospital, Zibo, Shandong 255300, China.
Yin
Y
Honglei
Neurology Department, General Hospital of Jinan Military Region, Jinan, Shandong 250031, China.
Cao
C
Xia
Department of Experimental Hematology, Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China.
Duan
D
Haifeng
Neurology Department, General Hospital of Jinan Military Region, Jinan, Shandong 250031, China.
Cao
C
Bingzhen